BACKGROUND: We present an uncommon case of a patient with hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis. The case demonstrates the importance of pre-transplant cardiology workup and the need of interdisciplinary approach in diagnosing the cause of dyspnoea. CASE SUMMARY: The 52-year-old male patient was diagnosed with idiopathic pulmonary fibrosis in 2019 and gradually became oxygen dependent due to progression of dyspnoea. Bilateral lung transplantation was recommended in 2021. During pre-transplant cardiology workup, the patient was diagnosed with hypertrophic cardiomyopathy with left ventricular outflow tract (LVOT) obstruction. Considering the high surgical risk of the patient, alcohol septal ablation was performed with subsequent decrease of LVOT gradient. Bilateral lung transplantation was successfully performed afterwards. The patient's symptoms improved to NYHA class II at one year follow-up. DISCUSSION: We present a rare case of combined cause of dyspnoea-coexistence of hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis in one patient. Due to high surgical risk, the patient underwent alcohol septal ablation with successful elimination of LVOT gradient and subsequently bilateral lung transplantation.

Department of Cardiology 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Uvalu 84 1 150 06 Prague Czech Republic

Prague Lung Transplant Program 3rd Department of Surgery 1st Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Hardy JD, Webb WR, Dalton ML Jr, Walker GR. Lung homotransplantation in man: report of the initial case. JAMA 1963;186:1065–1074. PubMed

Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med 2011;184:159–171. PubMed

De Vito Dabbs A, Song MK. Risk profile for cardiovascular morbidity and mortality after lung transplantation. Nurs Clin North Am 2008;43:37–53. PubMed

Chaikriangkrai K, Jyothula S, Jhun HY, Estep J, Loebe M, Scheinin S, et al. . Impact of pre-operative coronary artery disease on cardiovascular events following lung transplantation. J Heart Lung Transplantat 2016;35:115–121. PubMed

Kim HS, Park S. Recipient management before lung transplantation. J Chest Surg 2022;55:265–273. PubMed PMC

Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H, et al. . Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC expert panel. Am J Cardiol 2022;180:124–139. PubMed

Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. . Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003–2011. JAMA Cardiol 2016;1:324–332. PubMed

Veselka J, Faber L, Jensen MK, Cooper R, Januska J, Krejci J, et al. . Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol 2018;34:16–22. PubMed

Poon SS, Field M, Gupta D, Cameron D. Surgical septal myectomy or alcohol septal ablation: which approach offers better outcomes for patients with hypertrophic obstructive cardiomyopathy?. Interact Cardiovasc Thorac Surg 2017;24:951–961. PubMed

Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. . Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 2016;37:1517–1523. PubMed

Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv 2016;88:107–115. PubMed

Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. . Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 2022;80:95–108. PubMed